Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X about a recent article by Shuo Liu et al, published in Nature Biotechnology:
“Overcoming ICI resistance by reprogramming the tumor microenvironment
Immune checkpoint inhibitors often fail in the setting of an immunosuppressive TME. A new strategy tackles both barriers simultaneously.
What’s new:
- An inhalable bispecific exosome platform (BEAT) engineered to co-display two inhibitory ligands
- Uniform 1:1 surface presentation of PD-1 and FZD8 on exosomes
- Dual blockade of PD-L1 and Wnt7b, a key driver of immune exclusion via Wnt/β-catenin signaling
Why it matters:
- Recruits and activates CD8⁺ T cells
- Reprograms the tumor microenvironment
- Produces robust antitumor activity in ICI-resistant melanoma lung metastases
- Outperforms dual-antibody approaches in vivo
A compelling proof-of-concept that tandem protein display on exosomes may offer a scalable path to overcome immune resistance across solid tumors.”
Title: Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma
Authors: Shuo Liu, Mengrui Liu, Zhenzhen Wang, Shiqi Hu, Kaiyue Zhang, Chao Lu, Xiao Cheng, Ming Shen, Jianing Bi, Dashuai Zhu, Ke Cheng
Read the Full Article on Nature Biotechnology
More posts featuring Yan Leyfman.